-
AstraZeneca’s Gracell Biotechnologies to Expand Cell Therapy Manufacturing in China
•
Gracell Biotechnologies, a China-based cell therapy specialist owned by AstraZeneca (AZ; NASDAQ: AZN), is reportedly planning to expand its manufacturing capacity at its Suzhou BioBay life science cluster base, according to a report from Yicai Global. The construction of a 9,000 sq. m. expansion at the site is set to…
-
AstraZeneca to Acquire China’s Gracell Biotechnologies in $1.2 Billion Deal
•
Pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced its intention to fully acquire Gracell Biotechnologies Inc., (NASDAQ: GRCL), a China-based developer of chimeric antigen receptor (CAR) T cell therapies. This marks the first major merger and acquisition (M&A) deal by a foreign company targeting one of China’s newest generation biotechs.…
-
Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus
•
Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US Food and Drug Administration (FDA) to initiate a Phase I/II clinical study for its FasTCAR-T GC012F in the United States. The CAR-T therapy is set to be assessed as a treatment for refractory systemic lupus…
-
OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare
•
US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion for its latest private investment funds. The capital will be distributed among OrbiMed Private Investments IX, OrbiMed Asia Partners V, and OrbiMed Royalty & Credit Opportunities IV, reflecting the firm’s commitment to expanding its reach…
-
Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment
•
Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the second quarter of 2023. The report highlights the company’s core product, GC012F, which has shown excellent data in multiple melanoma (MM) studies, as a key focus of their strategy moving forward. Clinical Trials and Development…
-
Gracell Biotechnologies Secures $100 Million in Private Placement with Healthcare Investors
•
Suzhou-based biotech firm Gracell Biotechnologies Inc., (NASDAQ: GRCL) has announced a purchase agreement with a select group of institutional and accredited healthcare specialist investors for a private placement of 138,900,000 ordinary shares, equivalent to 27,780,000 American depositary shares (ADSs), at a purchase price of USD 3.60 per ADS. The agreement…
-
Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting
•
Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline candidate GC012F at the American Society of Clinical Oncology (ASCO) Annual Meeting. GC012F is a FasTCAR-T therapy targeting both B-cell maturation antigen (BCMA) and CD19, under development for the treatment of relapsed/refractory multiple myeloma (r/r…
-
Gracell Biotechnologies Initiates Trial for GC012F in Refractory SLE with Dual-Target FasTCAR Therapy
•
Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an investigator-initiated trial (IIT) in China for its therapeutic candidate GC012F. This candidate is an autologous FasTCAR therapy aimed at treating refractory systemic lupus erythematosus (SLE). The therapy is distinctive as a dual B cell maturation…
-
Gracell Secures Non-Exclusive License for Cell Therapies from Seagen
•
China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) has secured a non-exclusive worldwide license to develop and commercialize up to five cell therapy products from US biotech company Seagen Inc (ETR: PFE). The agreement was finalized on March 8, 2023, just days before Pfizer announced its intention to acquire Seagen for USD…
-
Gracell Biotechnologies Gains IND Approval for GC012F in China
•
Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) for its chimeric antigen receptor (CAR) T cell candidate GC012F. The dual BCMA/CD19-targeted therapy is set to be assessed in treating relapsed/refractory multiple myeloma (r/r MM), marking a significant step in the development…
-
Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval
•
Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US FDA for its chimeric antigen receptor (CAR) T cell candidate GC012F. This dual BCMA/CD19-targeted therapy is set to be assessed in treating relapsed/refractory multiple myeloma (r/r MM), marking a significant step forward in the development…
-
ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
•
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New Orleans, Louisiana, USA, saw the latest updates from a string of China-based biotechs. Those included CARsgen Therapeutics Holdings Ltd (HKG: 2171), Gracell Biotechnologies Inc (Nasdaq.GRCL), Innovent Biologics Inc., (HKG: 1801), Junshi Biosciences (HKG: 1877, SHA:…
-
Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award
•
China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this year’s Fierce Life Sciences Innovation Award. The announcement was made by Gracell CEO William Wei Cao during the firm’s Q3 earnings conference call. The FasTCAR platform enables the “next-day manufacture” of autologous chimeric antigen receptor…
-
Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients
•
China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion of its registrational Phase I/II clinical study assessing GC007g for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China. This milestone marks a significant step forward in the development of innovative treatments…
